Ovarian cancer

1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284-96.[Abstract][Full Text]

2. Fleming GF, Ronette BM, Seidman J, et al. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and practice of gynecologic oncology. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2009.

3. Ducie J, Dao F, Considine M, et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun. 2017 Oct 17;8(1):990.[Abstract][Full Text]

4. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017 Oct 23;8(1):1093.[Abstract][Full Text]

5. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.

6. Goff BA, Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12.[Abstract][Full Text]

7. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: ovarian cancer. 2024 [internet publication].[Full Text]

8. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49.[Abstract][Full Text]

9. World Health Organization. Cancer factsheets. 2024 [internet publication].​[Full Text]

10. Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan;136(1):3-7.[Abstract]

11. Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Apr 7;313(13):1347-61.[Abstract][Full Text]

12. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402-16.[Abstract][Full Text]

13. American College of Obstetricians and Gynecologists. Practice bulletin no 182: hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017 Sep;130(3):e110-26.[Abstract]

14. Bonadona V, Bonaïti B, Olschwang S, et al; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 Jun 8;305(22):2304-10.[Abstract][Full Text]

15. Peltomäki P. Update on Lynch syndrome genomics. Fam Cancer. 2016 Jul;15(3):385-93.[Abstract][Full Text]

16. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023 Jan;34(1):33-47.[Abstract][Full Text]

17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer/fallopian tube cancer/primary peritoneal cancer [internet publication].[Full Text]

18. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 147: Lynch syndrome. Obstet Gynecol. 2014 Nov;124(5):1042-54.[Abstract]

19. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007 Mar;5(1):35-44.[Abstract][Full Text]

20. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001 May 12;357(9267):1467-70.[Abstract]

21. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451-6.[Abstract]

22. Reade CJ, McVey RM, Tone AA, et al. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.[Abstract][Full Text]

23. Kurman RJ, Shih IeM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016 Apr;186(4):733-47.[Abstract][Full Text]

24. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. A mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005 Feb;29(2):218-24.[Abstract]

25. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994 Jan;12(1):64-9.[Abstract]

26. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005 Feb;18 Suppl 2:S19-32.[Abstract][Full Text]

27. Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016 Apr;2(4):482-90.[Abstract][Full Text]

28. Rose PG, Piver MS, Tsukada Y, et al. Metastatic patterns in histologic variants of ovarian cancer: an autopsy study. Cancer. 1989 Oct 1;64(7):1508-13.[Abstract]

29. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May;72(5):1117-30.[Abstract][Full Text]

30. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007 Apr 10;25(11):1329-33.[Abstract][Full Text]

31. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal [internet publication].[Full Text]

32. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol. 1992 Oct;80(4):700-7.[Abstract]

33. Kazerouni N, Greene MH, Lacey JV Jr, et al. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study. Cancer. 2006 Sep 1;107(5):1075-83.[Abstract][Full Text]

34. Ingham SL, Warwick J, Buchan I, et al. Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. J Med Genet. 2013 Jun;50(6):368-72.[Abstract]

35. Beral V, Doll R, Hermon C, et al; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008 Jan 26;371(9609):303-14.[Abstract]

36. Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013 Jul;122(1):139-47.[Abstract]

37. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018 Apr 1;4(4):516-21.[Abstract][Full Text]

38. Ness RB, Grisso JA, Klapper J, et al; SHARE Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000 Aug 1;152(3):233-41.[Abstract][Full Text]

39. Crane K. Oral contraceptives as ovarian cancer prevention. J Natl Cancer Inst. 2011 Sep 7;103(17):1286-8.[Abstract][Full Text]

40. Iversen L, Fielding S, Lidegaard Ø, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ. 2018 Sep 26;362:k3609.[Abstract][Full Text]

41. Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988 Dec;128(6):1228-40.[Abstract]

42. Tomao F, Lo Russo G, Spinelli GP, et al. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res. 2014 May 8;7:51.[Abstract][Full Text]

43. Babic A, Sasamoto N, Rosner BA, et al. Association between breastfeeding and ovarian cancer risk. JAMA Oncol. 2020 Jun 1;6(6):e200421.[Abstract][Full Text]

44. Sung HK, Ma SH, Choi JY, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. J Prev Med Public Health. 2016 Nov;49(6):349-66.[Abstract][Full Text]

45. Leitzmann MF, Koebnick C, Danforth KN, et al. Body mass index and risk of ovarian cancer. Cancer. 2009 Feb 15;115(4):812-22.[Abstract][Full Text]

46. Lauby-Secretan B, Scoccianti C, Loomis D, et al; International Agency for Research on Cancer Handbook Working Group. Body fatness and cancer - viewpoint of the IARC Working Group. N Engl J Med. 2016 Aug 25;375(8):794-8.[Abstract][Full Text]

47. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012;9(4):e1001200.[Abstract][Full Text]

48. Beral V, Gaitskell K, Hermon C, et al; Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015 May 9;385(9980):1835-42.[Abstract][Full Text]

49. Kim HS, Kim TH, Chung HH, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014 Apr 2;110(7):1878-90.[Abstract][Full Text]

50. Saavalainen L, Lassus H, But A, et al. Risk of gynecologic cancer according to the type of endometriosis. Obstet Gynecol. 2018 Jun;131(6):1095-102.[Abstract]

51. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993 Dec 15;270(23):2813-8.[Abstract]

52. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res. 2012 May 15;5(1):13.[Abstract][Full Text]

53. Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer prevention. Nov 2013 [internet publication].[Full Text]

54. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention. Obstet Gynecol. 2019 Apr;133(4):e279-84.[Abstract][Full Text]

55. van Lieshout LAM, Steenbeek MP, De Hullu JA, et al. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019 Aug 28;8(8):CD012858.[Abstract][Full Text]

56. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009 Jan 21;101(2):80-7.[Abstract][Full Text]

57. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002 May 23;346(21):1609-15.[Abstract][Full Text]

58. Ludwig KK, Neuner J, Butler A, et al. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016 Oct;212(4):660-9.[Abstract]

59. Paluch-Shimon S, Cardoso F, Sessa C, et al; ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016 Sep;27(suppl 5):v103-10.[Abstract][Full Text]

60. Eleje GU, Eke AC, Ezebialu IU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464.[Abstract][Full Text]

61. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic [internet publication].[Full Text]

62. Cannistra S. Medical progress: cancer of the ovary. N Engl J Med. 2004 Dec 9;351(24):2519-29.[Abstract]

63. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013 Nov 20;31(33):4188-98.[Abstract][Full Text]

64. Huber D, Seitz S, Kast K, et al. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Arch Gynecol Obstet. 2020 Apr;301(4):875-84.[Abstract]

65. Wheeler LJ, Desanto K, Teal SB, et al. Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2019 Oct;134(4):791-800.[Abstract]

66. Balayla J, Gil Y, Lasry A, et al. Ever-use of the intra-uterine device and the risk of ovarian cancer. J Obstet Gynaecol. 2021 Aug;41(6):848-53.[Abstract]

67. Goff BA, Mandel L, Muntz HG, et al. Ovarian cancer diagnosis: results of a national ovarian cancer survey. Cancer. 2000 Nov 15;89(10):2068-75.[Abstract]

68. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 716: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol. 2017 Sep;130(3):e146-9.[Abstract][Full Text]

69. Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016 Jul;61:137-45.[Abstract]

70. Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA. 2019 Aug 20;322(7):652-65.[Abstract][Full Text]

71. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol. 2020 Apr 10;38(11):1222-45.[Abstract][Full Text]

72. Committee on Gynecologic Practice. ACOG committee opinion no. 727: cascade testing: testing women for known hereditary genetic mutations associated with cancer. Obstet Gynecol. 2018 Jan;131(1):e31-4.[Abstract][Full Text]

73. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011 Mar;117(3):742-6.[Abstract]

74. Dodge JE, Covens AL, Lacchetti C, et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol. 2012 Aug;19(4):e244-57.[Abstract][Full Text]

75. American College of Radiology. ACR appropriateness criteria: clinically suspected adnexal mass, no acute symptoms​. 2023 [internet publication].[Full Text]

76. Karlan BY, Platt LD. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S28-33.[Abstract]

77. Kang SK, Reinhold C, Atri M, et al; Expert Panel on Women's Imaging. ACR appropriateness criteria: staging and follow-up of ovarian cancer. J Am Coll Radiol. 2018 May;15(5s):S198-207.[Abstract][Full Text]

78. Spencer JA. A multidisciplinary approach to ovarian cancer at diagnosis. Br J Radiol. 2005;78 Spec No 2:S94-102.[Abstract]

79. Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011 Jul;32(7):549-53.[Abstract]

80. Nie J, Zhang J, Gao J, et al. Diagnostic role of 18F-FDG PET/MRI in patients with gynecological malignancies of the pelvis: a systematic review and meta-analysis. PLoS One. 2017 May 8;12(5):e0175401.[Abstract][Full Text]

81. Tsuyoshi H, Tsujikawa T, Yamada S, et al. Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer. EJNMMI Res. 2020 Oct 2;10(1):117.[Abstract][Full Text]

82. González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.[Abstract][Full Text]

83. Garcia-Soto AE, Boren T, Wingo SN, et al. Is comprehensive surgical staging needed for thorough evaluation of early-stage ovarian carcinoma? Am J Obstet Gynecol. 2012 Mar;206(3):242.e1-5.[Abstract]

84. Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016 Oct 1;34(28):3460-73.[Abstract][Full Text]

85. Tuxen MK, Sölétormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995 May;21(3):215-45.[Abstract]

86. Einhorn N, Sjövall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14-8.[Abstract]

87. Vergote IB, Bormer OP, Abeler VM. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol. 1987 Jul;157(1):88-92.[Abstract]

88. Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016 Jan;26(1):43-51.[Abstract][Full Text]

89. Rustin GJ, van der Burg ME, Griffin CL, et al; MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010 Oct 2;376(9747):1155-63.[Abstract][Full Text]

90. Royal College of Obstetricians and Gynaecologists (UK). Management of ascites in ovarian cancer patients. Nov 2014 [internet publication].[Full Text]

91. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000 Aug;70(2):209-62.[Abstract]

92. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016 Feb 18;S0016-5085(16)00222-5.[Abstract]

93. de Waal YR, Thomas CM, Oei AL, et al. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer. 2009 Oct;19(7):1160-5.[Abstract]

94. Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and peri-operative characteristics. Gynecol Oncol. 2006 Apr;101(1):97-101.[Abstract]

95. Iida Y, Okamoto A, Hollis RL, et al. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021 Apr;31(4):605-16.[Abstract][Full Text]

96. Floch CL. Diagnosis and management of acute diverticulitis. J Clin Gastroenterol. 2006 Aug;40 Suppl 3:S136-44.[Abstract]

97. Amin MB, Edge SB, Greene FL, et al, eds. AJCC cancer staging manual, 8th edition. Cham, Switzerland: Springer International Publishing; 2017.

98. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014 Jan;124(1):1-5.[Abstract][Full Text]

99. Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.[Abstract][Full Text]

100. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40.[Abstract][Full Text]

101. Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 8;305(22):2295-303.[Abstract][Full Text]

102. Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 2016 Nov;143(2):270-5.[Abstract]

103. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021 Jun 5;397(10290):2182-93.[Abstract][Full Text]

104. Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer. 2012 May;22(Suppl 1):S24-6.[Abstract][Full Text]

105. Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 1;119(19):3454-61.[Abstract][Full Text]

106. Naumann RW, Brown J. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): good, bad, or just expensive? Gynecol Oncol. 2018 Apr;149(1):117-20.[Abstract]

107. Grossman DC, Curry SJ, Owens DK, et al; US Preventive Services Task Force. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018 Feb 13;319(6):588-94.[Abstract][Full Text]

108. Qaseem A, Humphrey LL, Harris R, et al; Clinical Guidelines Committee of the American College of Physicians. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Jul 1;161(1):67-72.[Abstract][Full Text]

109. American Academy of Family Physicians. Clinical preventive service recommendation: screening pelvic exam. 2017 [internet publication].[Full Text]

110. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 754 summary: the utility of and indications for routine pelvic examination. Obstet Gynecol. 2018 Oct;132(4):1080-3.[Abstract][Full Text]

111. Philpott S, Raikou M, Manchanda R, et al. The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2. J Med Genet. 2023 May;60(5):440-9.[Abstract][Full Text]

112. Manning-Geist BL, Flint M, Roche KL. Prevention over screening for ovarian cancer in patients with high-risk germline mutations: misinterpreting the findings of ALDO. Gynecol Oncol Rep. 2023 Apr;46:101157.[Abstract][Full Text]

113. Pandharipande PV, Lowry KP, Reinhold C, et al; Expert Panel on Women's Imaging. ACR appropriateness criteria: ovarian cancer screening. J Am Coll Radiol. 2017 Nov;14(11s):S490-9.[Abstract][Full Text]

114. American College of Obstetricians and Gynecologists. Practice bulletin no 174. Summary: evaluation and management of adnexal masses. Obstet Gynecol. 2016 Nov;128(5):1193-5.[Abstract]

115. Ledermann JA, Matias-Guiu X, Amant F, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024 Mar;35(3):248-66.[Abstract][Full Text]

116. National Institute for Health and Care Excellence. Ovarian cancer: recognition and initial management. Oct 2023 [internet publication].[Full Text]

117. Ray-Coquard I, Morice P, Lorusso D, et al; ESMO Guidelines Committee. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(suppl 4):iv1-18.[Abstract][Full Text]

118. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59.[Abstract]

119. Kehoe S, Powell J, Wilson S, et al. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer. 1994 Nov;70(5):1014-7.[Abstract]

120. Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006 Feb 1;98(3):172-80.[Abstract][Full Text]

121. Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006 Feb 1;106(3):589-98.[Abstract][Full Text]

122. Le T, Giede C, Salem S, et al; Society of Obstetricians and Gynaecologists of Canada. Initial evaluation and referral guidelines for management of pelvic/ovarian masses. J Obstet Gynaecol Can. 2009 Jul;31(7):668-80.[Abstract]

123. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983 Dec 9;250(22):3072-6.[Abstract]

124. Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer. 2017 Sep;27(7):1534-42.[Abstract][Full Text]

125. Rosendahl M, Haueberg Oester LA, Høgdall CK. The importance of appendectomy in surgery for mucinous adenocarcinoma of the ovary. Int J Gynecol Cancer. 2017 Mar;27(3):430-6.[Abstract]

126. Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019 Feb 28;380(9):822-32.[Abstract][Full Text]

127. Chiyoda T, Sakurai M, Satoh T, et al. Lymphadenectomy for primary ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol. 2020 Sep;31(5):e67.[Abstract][Full Text]

128. Gerestein CG, Damhuis RA, Burger CW, et al. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009 Sep;114(3):523-7.[Abstract]

129. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009 Mar 15;115(6):1234-44.[Abstract][Full Text]

130. van de Vrie R, Rutten MJ, Asseler JD, et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database Syst Rev. 2019 Mar 23;(3):CD009786.[Abstract][Full Text]

131. Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol. 2010 Summer;3(3):111-7.[Abstract]

132. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer - results of two prospective randomized trials. N Engl J Med. 1990 Apr 12;322(15):1021-7.[Abstract][Full Text]

133. Lawrie TA, Winter-Roach BA, Heus P, et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2015 Dec 17;(12):CD004706.[Abstract][Full Text]

134. Timmers PJ, Zwinderman AH, Coens C, et al. Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer. 2010 Mar;46(5):880-4.[Abstract]

135. Bell J, Brady MF, Young RC, et al; Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Sep;102(3):432-9.[Abstract]

136. Vasey PA, Atkinson R, Osborne R, et al. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer. 2006 Jan 16;94(1):62-8.[Abstract][Full Text]

137. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91.[Abstract][Full Text]

138. Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011 Sep 20;29(27):3628-35.[Abstract][Full Text]

139. Ozols RF, Bundy BM, Greer BE, et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200.[Abstract]

140. Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83.[Abstract][Full Text]

141. Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2484-96.[Abstract][Full Text]

142. Burger RA, Brady MF, Rhee J, et al. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol. 2013 Oct;131(1):21-6.[Abstract]

143. Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019 Sep 10;37(26):2317-28.[Abstract][Full Text]

144. González Martín A, Oza AM, Embleton AC, et al; ICON7 Investigators. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol. 2019 Jan;152(1):53-60.[Abstract][Full Text]

145. du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9.[Abstract][Full Text]

146. Amate P, Huchon C, Dessapt AL, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013 Nov;23(9):1590-6.[Abstract]

147. Fung-Kee-Fung M, Provencher D, Rosen B, et al; IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol. 2007 Jun;105(3):747-56.[Abstract]

148. Armstrong DK, Bundy B, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.[Abstract][Full Text]

149. Markman M, Bundy BM, Alberts DS, et al. Phase III trial of standard dose intravenous carboplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7.[Abstract]

150. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5.[Abstract][Full Text]

151. Wenzel LB, Huang HQ, Armstrong DK, et al; Gynecologic Oncology Group. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007 Feb 1;25(4):437-43.[Abstract][Full Text]

152. Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000 Feb;76(2):157-62.[Abstract]

153. Walker JL, Brady MF, Wenzel L, et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2019 Jun 1;37(16):1380-90.[Abstract][Full Text]

154. Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol. 2007 Feb;104(2):480-90.[Abstract]

155. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, et al. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2016 Jan 9;(1):CD006014.[Abstract][Full Text]

156. Coleridge SL, Bryant A, Kehoe S, et al. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021 Jul 30;(7):CD005343.[Abstract][Full Text]

157. Zhang H, Huang Z, Zou X, et al. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016 Dec 13;7(50):82473-81.[Abstract][Full Text]

158. Turco LC, Ferrandina G, Vargiu V, et al. Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature. Ann Transl Med. 2020 Dec;8(24):1687.[Abstract][Full Text]

159. Vergote I, Trope CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53.[Abstract][Full Text]

160. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015 Jul 18;386(9990):249-57.[Abstract]

161. Tiersten AD, Liu PY, Smith HO, et al. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. Gynecol Oncol. 2009 Mar;112(3):444-9.[Abstract]

162. Provencher DM, Gallagher CJ, Parulekar WR, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018 Feb 1;29(2):431-8.[Abstract][Full Text]

163. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol. 2020 Jun;27(3):146-54.[Abstract][Full Text]

164. Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 2002 Mar-Apr;22(2b):1329-36.[Abstract]

165. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998 Jan;34(1):148-54.[Abstract]

166. Kireeva GS, Gafton GI, Guseynov KD, et al. HIPEC in patients with primary advanced ovarian cancer: is there a role? A systematic review of short- and long-term outcomes. Surg Oncol. 2018 Jun;27(2):251-8.[Abstract]

167. van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018 Jan 18;378(3):230-40.[Abstract][Full Text]

168. Koole S, van Stein R, Sikorska K, et al; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. Int J Gynecol Cancer. 2020 Jun;30(6):888-92.[Abstract][Full Text]

169. Katsumata N, Yasuda M, Takahashi F, et al; Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1331-8.[Abstract]

170. Katsumata N, Yasuda M, Isonishi S, et al; Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013 Sep;14(10):1020-6.[Abstract]

171. Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014 Apr;15(4):396-405.[Abstract]

172. Gourley C, Bookman MA. Evolving concepts in the management of newly diagnosed epithelial ovarian cancer. J Clin Oncol. 2019 Sep 20;37(27):2386-97.[Abstract]

173. Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016 Feb 25;374(8):738-48.[Abstract][Full Text]

174. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019 Dec 7;394(10214):2084-95.[Abstract][Full Text]

175. Blagden SP, Cook AD, Poole C, et al. Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020 Jul;21(7):969-77.[Abstract][Full Text]

176. Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81[Abstract][Full Text]

177. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003 Jul 1;21(13):2460-5.[Abstract]

178. Copeland LJ, Brady MF, Burger RA et al. Phase III trial of maintenance therapy in women with advanced ovary/tubal/peritoneal cancer after a complete response to first-line therapy: an NRG oncology (GOG Legacy) study. Abstract LBA1. Paper presented at: 48th Annual Meeting of the Society of Gynecologic Oncology. 12-15 Mar 2017. National Harbor, MD.

179. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: from bench to bedside. Ann Oncol. 2011 Feb;22(2):268-79.[Abstract]

180. Medicines and Healthcare products Regulatory Agency (UK). Drug safety update. Niraparib (Zejula): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment. Oct 2020 [internet publication].[Full Text]

181. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006 May 1;106(9):1933-9.[Abstract][Full Text]

182. Schorge JO, Wingo SN, Bhore R, et al. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010 Feb;108(2):123-7.[Abstract]

183. Du Bois A, Sehouli J, Vergote I, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. Paper presented at: 2020 American Society of Clinical Oncology Annual Meeting. 29-31 May 2020. Abstract 6000. J Clin Oncol. 2020;38(15 suppl):6000.[Full Text]

184. Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):439-49.[Abstract]

185. Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019 Nov 14;381(20):1929-39.[Abstract][Full Text]

186. Harter P, Sehouli J, Vergote I, et al; DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med. 2021 Dec 2;385(23):2123-31.[Abstract][Full Text]

187. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011 Feb;21(2):289-95.[Abstract]

188. Ding T, Tang D, Xi M. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis. J Ovarian Res. 2021 Jul 13;14(1):93.[Abstract][Full Text]

189. Pujade-Lauraine E, Wagner U, Avall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9.[Abstract][Full Text]

190. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012 Aug 7;107(4):588-91.[Abstract][Full Text]

191. Pfisterer J, Plante M, Vergote I, et al; AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006 Oct 10;24(29):4699-707.[Abstract][Full Text]

192. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106.[Abstract]

193. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.[Abstract][Full Text]

194. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):779-91.[Abstract]

195. Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 May;21(5):699-709.[Abstract]

196. Hanker LC, Loibl S, Burchardi N, et al; AGO and GINECO Study Group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012 Oct;23(10):2605-12.[Abstract][Full Text]

197. González-Martín A, Pothuri B, Vergote I, et al; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2391-402.[Abstract][Full Text]

198. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92.[Abstract][Full Text]

199. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-84.[Abstract]

200. Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018 Aug;19(8):1126-34.[Abstract]

201. Poveda A, Floquet A, Ledermann JA, et al; SOLO2/ENGOT-Ov21 Investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620-31.[Abstract]

202. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64.[Abstract][Full Text]

203. Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug;19(8):1117-25.[Abstract]

204. Matulonis UA, Walder L, Nøttrup TJ, et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16/NOVA trial. J Clin Oncol. 2019 Dec 1;37(34):3183-91.[Abstract][Full Text]

205. Coleman RL, Oza AM, Lorusso D, et al; ARIEL3 Investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-61.[Abstract]

206. GSK. GSK provides an update on Zejula (niraparib) US prescribing information. Nov 2022 [internet publication].[Full Text]

207. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001034.[Abstract][Full Text]

208. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8.[Abstract][Full Text]

209. Wang X, Bao Z, Zhang X, et al. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget. 2017 Aug 29;8(35):59901-14.[Abstract][Full Text]

210. US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. May 2017 [internet publication].[Full Text]

211. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 Oct;21(10):1353-65.[Abstract]

212. Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 Jul 1;30(7):1080-7.[Abstract][Full Text]

213. Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019 Aug 1;5(8):1141-9.[Abstract][Full Text]

214. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: a combined analysis of two cohorts in the GARNET study. Paper presented at: 2021 American Society of Clinical Oncology Annual Meeting. 4-8 Jun 2021. Abstract 2564. J Clin Oncol, 2021;39(15_suppl):2564.[Full Text]

215. Musacchio L, Salutari V, Pignata S, et al. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). Int J Gynecol Cancer. 2021 Oct;31(10):1369-73.[Abstract]

216. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 Jun;32(6):757-65.[Abstract][Full Text]

217. Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020 Mar;156(3):535-44.[Abstract]

218. Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-74.[Abstract][Full Text]

219. Ledermann JA, Embleton-Thirsk AC, Perren TJ, et al. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open. 2021 Apr;6(2):100043.[Abstract][Full Text]

220. Liu JF, Brady MF, Matulonis UA, et al. Olaparib with or without cediranib versus platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (NRG-GY004): a randomized, open-label, phase III trial. J Clin Oncol. 2022 Jul 1;40(19):2138-47.[Abstract][Full Text]

221. Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 Jul;15(8):799-808.[Abstract]

222. Vergote I, Scambia G, O'Malley DM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):862-76.[Abstract]

223. Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015 May;16(5):561-8.[Abstract]

224. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018 Feb 1;4(2):196-202.[Abstract][Full Text]

225. du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82.[Abstract][Full Text]

226. Vergote I, du Bois A, Floquet A, et al. Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-91.[Abstract][Full Text]

227. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF-V600E mutations: results of the NCI-MATCH Trial subprotocol H. J Clin Oncol. 2020 Nov 20;38(33):3895-904.[Abstract][Full Text]

228. National Cancer Institute. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment. Apr 2024 [internet publication].[Full Text]

229. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol. 1999;10(suppl 1):35-41.[Abstract]

230. Maxwell GL, Synan I, Dodge R, et al. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001 Dec;98(6):989-95.[Abstract]

231. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998 Feb;16(2):405-10.[Abstract]

232. National Cancer Institute: Surveillance, Epidemiology, and End Results Program​. An interactive website for SEER cancer statistics. Apr 2024 [internet publication].[Full Text]

233. Lippitt MH, Fairbairn MG, Matsuno R, et al. Outcomes associated with a five-point surgical site infection prevention bundle in women undergoing surgery for ovarian cancer. Obstet Gynecol. 2017 Oct;130(4):756-64.[Abstract]

234. Holschneider CH, Berek JS. Cytoreductive surgery: principles and rationale. In: Bristow RE, Karlan BY, eds. Surgery for ovarian cancer: principles and practice. London, UK: Taylor and Francis; 2006:99-101.

235. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006 Dec 21;355(25):2640-51.[Abstract][Full Text]

236. Madjdpour C, Spahn DR, Weiskopf RB. Anemia and perioperative red blood cell transfusion: a matter of tolerance. Crit Care Med. 2006 May;34(5 Suppl):S102-8.[Abstract]

237. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016 Nov 15;316(19):2025-35.[Abstract]

238. De Oliveira GS Jr, Schink JC, Buoy C, et al. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfus Med. 2012 Apr;22(2):97-103.[Abstract]

239. Cheatham ML, Chapman WC, Key SP, et al. A meta-analysis of selective versus routine nasogastric decompression after elective laparotomy. Ann Surg. 1995 May;221(5):469-76.[Abstract][Full Text]

240. Sowerbutts AM, Lal S, Sremanakova J, et al. Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev. 2018 Aug 10;8(8):CD012812.[Abstract][Full Text]

241. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine. 1999 Sep;78(5):285-91.[Abstract]

242. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944.[Abstract][Full Text]

243. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004 Feb 3;140(3):175-83.[Abstract]

244. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975-80.[Abstract]

245. Di Donato V, Kontopantelis E, Aletti G, et al. Trends in mortality after primary cytoreductive surgery for ovarian cancer: a systematic review and metaregression of randomized clinical trials and observational studies. Ann Surg Oncol. 2017 Jun;24(6):1688-97.[Abstract]

246. Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol. 1999 Jan;72(1):93-9.[Abstract]

247. Yang L, Zhang B, Xing G, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome. PLoS One. 2017 Oct 23;12(10):e0186725.[Abstract][Full Text]

248. Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ. 2018 Jan 3;360:j5463.[Abstract][Full Text]

249. Rubin SC, Hoskins WJ, Benjamin I, et al. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 1989 Jul;34(1):16-9.[Abstract]

250. Numnum TM, Rocconi RP, Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian cancer. Gynecol Oncol. 2006 Sep;102(3):425-8.[Abstract]

251. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002 May 1;20(9):2365-9.[Abstract]

252. Torramadé JR, Cienfuegos JA, Hernández, et al. The complications of central venous access systems: a study of 218 patients. Eur J Surg. 1993 Jun-Jul;159(6-7):323-7.[Abstract]

253. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Jan;100(1):27-32.[Abstract]

254. Risum S, Langer SW. Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment [in Danish]. Ugeskr Laeger 2003 Aug 11;165(33):3161-2.[Abstract]

255. Lopez AM, Wallace L, Dorr RT, et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 1999;44(4):303-6.[Abstract]

256. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34.[Abstract]

257. Schaffrin-Nabe D, Schmitz I, Josten-Nabe A, et al. The influence of various parameters on the success of sensor-controlled scalp cooling in preventing chemotherapy-induced alopecia. Oncol Res Treat. 2015;38(10):489-95.[Abstract]

258. Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010 Jul;118(1):47-51.[Abstract]

259. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25(33):5180-6.[Abstract][Full Text]

260. Clarke T, Galaal K, Bryant A, et al. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2014 Sep 8;(9):CD006119.[Abstract][Full Text]

261. Geurts SM, de Vegt F, van Altena AM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011 Jul;21(5):837-45.[Abstract]

262. Lajer H, Jensen MB, Kilsmark J, et al. The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer. 2010 Nov;20(8):1307-20.[Abstract]

263. Society of Gynecologic Oncologists. Use of CA125 for monitoring ovarian cancer. Jun 2009 [internet publication].[Full Text]